Japan Draws Global Firms Intent On Continuing To Market Off-Patent Drugs
This article was originally published in PharmAsia News
Executive Summary
Japan is seen by multinational drug makers as presenting a chance to reverse past tactics and continue building sales for drugs nearing or having reached off-patent status